The content on this site is intended for healthcare professionals only
Dr Josep Ribera talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about the how to best use TKIs in Ph-positive ALL.
Dr Ribera states that it's possible that using TKIs (tyrosine kinase inhibitors) could become the standard for treating Ph-positive ALL patients.
He also outlines several promising strategies for treating patients suffering with relapsed refractory ALL.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
EHA 2024: Multiple myeloma roundup
More effective treatment options required for patients with MM post lenalidomide exposure
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Multiple myeloma in a resource constrained setting
Ide-cell enhances health-related quality of life for refractory multiple myeloma
